WILMINGTON, Mass., March 9 DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 22nd Annual OC Growth Stock Conference. The conference is being held at the Ritz-Carlton Laguna Niguel, Dana Point, California on March 15-17, 2010. Mr. Doman is scheduled to present at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) on March 16, 2010. Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately three hours following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(®) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(®) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(®). DUSA is researching the use of broad area Levulan(®) PDT to treat AKs and prevent squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.